Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis
- 24 October 2011
- journal article
- review article
- Published by WHO Press in Bulletin of the World Health Organization
- Vol. 90 (2), 128-138C
- https://doi.org/10.2471/blt.11.093260
Abstract
Objective To determine whether cotrimoxazole reduces mortality in adults receiving antiretroviral therapy (ART) for human immunodeficiency virus (HIV) infection in low- and middle-income countries through a systematic review and meta-analysis. Methods PubMed and Embase were searched for randomized controlled trials and prospective and retrospective cohort studies that compared mortality or morbidity in HIV-infected individuals aged >= 13 years on cotrimoxazole and ART and on ART alone. The Newcastle-Ottawa Quality Assessment Scale was used to assess selection, confounding and measurement bias. Publication bias was assessed using Egger's and Begg's tests. Sensitivity analysis was performed because the I-squared statistic indicated substantial heterogeneity in study results, A random-effects model was used for meta-analysis. Findings Nine studies were included. Begg and Egger P-values for the seven that reported the effect of cotrimoxazole on mortality were 0.29 and 0.49, respectively, suggesting no publication bias. The I-squared statistic was 93.2%, indicating high heterogeneity in study results. The sensitivity analysis showed that neither the follow-up duration nor the percentage of individuals with World Health Organization stage 3 or 4 HIV disease at baseline explained the heterogeneity. The summary estimate of the effect of cotrimoxazole on the incidence rate of death was 0.42 (95% confidence interval: 0.29-0.61). Since most studies followed participants for less than 1 year, it was not possible to determine whether cotrimoxazole can be stopped safely after ART-induced immune reconstitution. Conclusion Cotrimoxazole significantly increased survival in HIV-infected adults on ART. Further research is needed to determine the optimum duration of cotrimoxazole treatment in these patients.Keywords
This publication has 40 references indexed in Scilit:
- Implementation of free cotrimoxazole prophylaxis improves clinic retention among antiretroviral therapy-ineligible clients in KenyaAIDS, 2011
- Community-based intervention to increase HIV testing and case detection in people aged 16–32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised studyThe Lancet Infectious Diseases, 2011
- Outcomes in patients waiting for antiretroviral treatment in the Free State Province, South Africa: prospective linkage studyAIDS, 2010
- Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002–2007AIDS, 2010
- Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South AfricaAIDS, 2010
- Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohortThe Lancet, 2010
- Mortality During the First Year of Potent Antiretroviral Therapy in HIV-1-Infected Patients in 7 Sites Throughout Latin America and the CaribbeanJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Predictors of Adherence to Antiretroviral Therapy in Rural ZambiaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Measuring inconsistency in meta-analysesBMJ, 2003
- Quantifying heterogeneity in a meta-analysisStatistics in Medicine, 2002